AR039673A1 - Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metodos para su aplicacion - Google Patents

Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metodos para su aplicacion

Info

Publication number
AR039673A1
AR039673A1 ARP030102121A ARP030102121A AR039673A1 AR 039673 A1 AR039673 A1 AR 039673A1 AR P030102121 A ARP030102121 A AR P030102121A AR P030102121 A ARP030102121 A AR P030102121A AR 039673 A1 AR039673 A1 AR 039673A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
membered heterocycle
cycloalkyl
independently selected
Prior art date
Application number
ARP030102121A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR039673A1 publication Critical patent/AR039673A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composiciones farmacéuticas que contiene los compuestos de fórmula (1) y a métodos para tratar trastornos hiperproliferativos en un mamífero administrando los compuestos de fórmula (1). Estos compuestos son útiles en el tratamiento de enfermedades. Reivindicación 1: Un compuesto representando por la fórmula (1) caracterizado porque: Y es -NH-, -O-, -S-, o -CH2-; Z es -O-, -S-, o -N-; R14 es un alquilo C1-6, alquil(C1-6)-amino, alquil(C1-6)-hidroxi, cicloalquil(C3-10)-amino, o grupo metilureido; R15 y R17 son independientemente H, halo, o un grupo alquilo C1-6 sin sustituir o sustituido con uno o más grupos R5; R16 es H o un grupo alquilo C1-6 Z es N, y R16 está ausente cuando Z es -O- o -S-; R11 es H, alquilo C1-6, cicloalquilo C3-10, -C(O)NR12R13, -C(O)(arilo C1-6); -(CH2)t(arilo C6-10), -(CH2)t(heterociclo de 5 a 10 miembros), -(CH2)tNR12R13, -SO2NR12R13 o -CO2R12, en la que dicho alquilo C1-6, -C(O)(arilo C6-10), -(CH2)t(arilo C6-10), y restos -(CH2)t(heterociclo de 5 a 10 miembros) de dichos grupos R11 están sin sustituir o sustituidos con uno o más grupos R5; cada R5 se selecciona independientemente de halo, ciano, nitro, trifluorometoxi, trifluorometilo, azido, -C(O)R8, -C(O)OR8, -OC(O)R8, -OC(O)OR8, -NR6C(O)R7, -C(O)NR6R7, -NR6R7, -OR9, -SO2NR6R7, alquilo C1-6, cicloalquilo C3-10, alquil(C1-6)-amino, -(CH2)jO(CH2)qNR6R7, (CH2)tO(CH2)qOR9, (CH2)tOR9, -S(O)j(alquilo C1-6), -(CH2)t(arilo C6-10), -(CH2)t(heterociclo de 5 a 10 miembros), -C(O)(CH2)t(arilo C6-10), -(CH2)tO(CH2)j(arilo C6-10), -(CH2)tO(CH2)q(heterociclo de 5 a 10 miembros), -C(O)(CH2)t(heterociclo de 5 a 10 miembros), -(CH2)jNR7(CH2)qNR6R7, -(CH2)jNR7CH2C(O)NR6R7, -(CH2)jNR7(CH2)qNR9C(O)R8, -(CH2)jNR7(CH2)tO(CH2)qOR9, -(CH2)jNR7(CH2)qS(O)j(alquilo C1-6), -(CH2)jNR7(CH2)tR6, -SO2(CH2)t(arilo C6-10), y -SO2(CH2)t(heterociclo de 5 a 10 miembros), los restos -(CH2)q- y -(CH2)t- de dichos grupos R5 opcionalmente incluyen un doble o triple enlace carbono-carbono, y el alquilo, arilo y restos heterocíclicos de dichos grupos R5 están sin sustituir o sustituidos con uno o más sustituyentes independientemente seleccionados de halo, ciano, nitro, trifluorometilo, azido, -OH, -C(O)R8, -C(O)OR8, -OC(O)R8, -OC(O)OR8, -NR6C(O)R7, -C(O)NR6R7, -(CH2)tNR6R7, alquilo C1-6, cicloalquilo C3-10, -(CH2)t(arilo C6-10), -(CH2)t(heterociclo de 5 a 10 miembros), -(CH2)tO(CH2)qOR9, y -(CH2)tOR9; cada R6 y R7 se selecciona independientemente de H, OH, alquilo C1-6, cicloalquilo C3-10, -(CH2)t(arilo C6-10), -(CH2)t((heterociclo de 5 a 10 miembros), -(CH2)tO(CH2)qOR9, -(CH2)tCN(CH2)tOR9, -(CH2)tCN(CH2)tR9 y -(CH2)tOR9, y el alquilo, arilo y restos heterocíclicos de dichos grupos R6 y R7 están sin sustituir o sustituidos con uno o más sustituyentes independientemente seleccionados de hidroxi, halo, ciano, nitro, trifluorometilo, azido, -C(O)R8, -C(O)OR8, -CO(O)R8, -OC(O)OR8, -NR9C(O)R10, -C(O)NR9R10, -NR9R10, alquilo C1-6, -(CH2)t(arilo C6-10), -(CH2)t(heterociclo de 5 a 10 miembros), -(CH2)tO(CH2)qOR9, y -(CH2)tOR9, en los que cuando R6 y R7 están ambos unidos al mismo nitrógeno, entonces R6 y R7 no están ambos unidos al nitrógeno directamente por medio de un oxígeno; cada R8 se selecciona independientemente de H, alquilo C1-10, cicloalquilo c3-10, -(CH2)t(arilo C6-10), y -(CH2)t(heterociclo de 5 a 10 miembros); t es un número entero de 0 a 6; j es un número entero de 0 a 2, q es un número entero de 2 a 6; cada R9 y R10 se selecciona independientemente de H, -OR6, alquilo C1-6 y cicloalquilo C3-10; y cada R12 y R13 se selecciona independientemente de H, alquilo C1-6, cicloalquilo C3-10, -(CH2)t(cicloalquilo C3-10), -(CH2)t(arilo C6-10), -(CH2)t(heterociclo de 5 a 10 miembros), -(CH2)tO(CH2)qOR9, y -(CH2)tOR9, y el alquilo, arilo y restos heterocíclicos de dichos grupos R12 y R13 están sin sustituir o sustituidos con uno o más sustituyentes independientemente seleccionados de R5, o R12 y R13 se toman conjuntamente con el nitrógeno al que están unidos para formar un anillo azabiciclo C5-9, aziridinilo, azetidinilo, pirrolidinilo, piperidinilo, piperazinilo, morfolinilo, tiomorfolinilo, isoquinolinilo o dihidroisoquinolinilo, en los que dichos anillos azabiciclo C5-9, aziridinilo, azetidinilo, pirrolidinilo, piperidinilo, piperazinilo, morfolinilo, tiomorfolinilo, isoquinolinilo o dihidroisoquinolinilo están sustituidos o sin sustituir con uno o más sustituyentes R5, en los que R12 y R13 no están ambos unidos al nitrógeno directamente por medio de un oxígeno; o sus profármacos o metabolitos, o sales o solvatos farmacéuticamente aceptables de dichos compuestos y dichos profármacos y dichos metabolitos.
ARP030102121A 2002-06-14 2003-06-13 Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metodos para su aplicacion AR039673A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38911002P 2002-06-14 2002-06-14

Publications (1)

Publication Number Publication Date
AR039673A1 true AR039673A1 (es) 2005-03-09

Family

ID=29736588

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102121A AR039673A1 (es) 2002-06-14 2003-06-13 Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metodos para su aplicacion

Country Status (36)

Country Link
US (3) US6869962B2 (es)
EP (1) EP1515975B1 (es)
JP (1) JP2005534669A (es)
KR (2) KR100714545B1 (es)
CN (1) CN1671714A (es)
AP (1) AP2004003184A0 (es)
AR (1) AR039673A1 (es)
AT (1) ATE373665T1 (es)
AU (1) AU2003233134A1 (es)
BR (1) BR0311806A (es)
CA (1) CA2489466A1 (es)
CO (1) CO5631447A2 (es)
DE (1) DE60316440T2 (es)
EA (1) EA008255B1 (es)
EC (1) ECSP045483A (es)
ES (1) ES2290460T3 (es)
GE (1) GEP20074033B (es)
GT (1) GT200300129A (es)
HN (1) HN2003000182A (es)
HR (1) HRP20041173A2 (es)
IL (1) IL165591A0 (es)
IS (1) IS7552A (es)
MA (1) MA27596A1 (es)
MX (1) MXPA04011637A (es)
NO (1) NO20045103L (es)
NZ (1) NZ537140A (es)
OA (1) OA12865A (es)
PA (1) PA8575401A1 (es)
PE (1) PE20050123A1 (es)
PL (1) PL374542A1 (es)
RS (1) RS107504A (es)
TN (1) TNSN04246A1 (es)
TW (1) TW200404070A (es)
UA (1) UA77303C2 (es)
WO (1) WO2003106462A1 (es)
ZA (1) ZA200409862B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE399766T1 (de) * 2000-10-20 2008-07-15 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische heterozyklen
AU2003270285B2 (en) 2002-10-03 2007-04-26 F. Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (GK) activators
EP1604665B1 (en) * 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
CN101337930B (zh) * 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
EP1711495A2 (en) * 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
EP1797877A4 (en) 2004-09-13 2010-12-15 Eisai Co Ltd JOINT USE OF A SULFONAMIDE-BASED COMPOUND AND AN ANGIOGENESIS INHIBITOR
US8772269B2 (en) * 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
WO2006043172A1 (en) * 2004-10-19 2006-04-27 Pfizer Inc. Pharmaceutical compositions and methods for sub-tenon delivery
WO2006117666A2 (en) * 2005-04-29 2006-11-09 Pfizer Inc. Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
US20100105031A1 (en) * 2005-08-01 2010-04-29 Esai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
JP5209966B2 (ja) * 2005-09-01 2013-06-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 崩壊性の改善された医薬組成物の製造方法
AR055625A1 (es) * 2005-09-02 2007-08-29 Pfizer Procedimientos mejorados para preparar derivados de tienopiridinas heteroaril amida benzocondensados
CA2627598C (en) 2005-11-07 2013-06-25 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
EP1964837A4 (en) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Antitumor agent against multiple myeloma
TW200806675A (en) * 2006-01-30 2008-02-01 Array Biopharma Inc Heterobicyclic thiophene compounds and methods of use
KR20080102181A (ko) * 2006-02-15 2008-11-24 알러간, 인코포레이티드 스핑고신-1-포스페이트 (에스1피) 수용체 길항제 생물학적 활성을 갖는 아릴 또는 헤테로아릴기를 포함하는 인돌-3-카르보실산 아미드, 에스테르, 티오아미드 및 티올 에스테르 화합물
GB0604937D0 (en) * 2006-03-10 2006-04-19 Novartis Ag Organic compounds
CN101443009A (zh) * 2006-05-18 2009-05-27 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
WO2008001956A1 (fr) * 2006-06-29 2008-01-03 Eisai R & D Management Co., Ltd. Agent thérapeutique contre la fibrose hépatique
US8865737B2 (en) * 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
JP5319306B2 (ja) * 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
EP2183255A4 (en) * 2007-08-29 2011-06-15 Methylgene Inc METHOD AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF CONDENSED HETEROCYCLIC KINASE INHIBITORS
RU2495044C2 (ru) * 2007-08-29 2013-10-10 Метилджен Инк. Ингибиторы активности протеинтирозинкиназы
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
JP5399926B2 (ja) * 2008-01-29 2014-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管阻害物質とタキサンとの併用
CA2719745C (en) * 2008-03-25 2016-07-05 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
US8815892B2 (en) 2008-03-25 2014-08-26 Affectis Pharmaceuticals Ag P2X7R antagonists and their use
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
KR20120047313A (ko) * 2009-09-03 2012-05-11 알러간, 인코포레이티드 티로신 키나제 조절인자로서의 화합물
WO2011073521A1 (en) 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
WO2011162343A1 (ja) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
SG187592A1 (en) 2010-07-23 2013-03-28 Univ Boston Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
JP6411379B2 (ja) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
EP3825305A1 (en) 2014-08-28 2021-05-26 Eisai R&D Management Co., Ltd. Process for preparing lenvatinib
CN104628686A (zh) * 2015-01-27 2015-05-20 南通恒盛精细化工有限公司 一种带酰胺侧链的苯并呋喃制备工艺
PT3263106T (pt) 2015-02-25 2024-01-12 Eisai R&D Man Co Ltd Método para suprimir o amargor do derivado de quinolina
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
KR20180018695A (ko) 2015-06-16 2018-02-21 가부시키가이샤 프리즘 파마 항암제
CN109053524A (zh) * 2018-09-11 2018-12-21 山东谛爱生物技术有限公司 一种N-Boc-3-羟基氮杂环丁烷的制备方法
US20220056043A1 (en) * 2019-02-19 2022-02-24 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nitrogen-containing fused cyclic compound, preparation method therefor and use thereof
WO2021057256A1 (zh) * 2019-09-29 2021-04-01 四川科伦博泰生物医药股份有限公司 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559616A (en) * 1984-10-03 1985-12-17 Quadri Corporation Fast, non-volatile semiconductor/bubble memory with temperature-compensated magnetic bias field
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
EP0746554A1 (en) 1994-02-23 1996-12-11 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
AU700964B2 (en) 1994-11-10 1999-01-14 Cor Therapeutics, Inc. Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
EP2295415A1 (en) 1995-03-30 2011-03-16 OSI Pharmaceuticals, Inc. Quinazoline derivatives
US5861510A (en) 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
MX9709867A (es) 1995-06-07 1998-03-31 Pfizer Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos.
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
US6514971B1 (en) 1996-03-15 2003-02-04 Zeneca Limited Cinnoline derivatives and use as medicine
WO1997049688A1 (en) 1996-06-24 1997-12-31 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
AU2710597A (en) 1996-06-27 1998-01-14 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
JP3195756B2 (ja) 1996-07-04 2001-08-06 公子 吉水 潤滑補助体
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
WO1998002434A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
DE69718472T2 (de) 1996-07-13 2003-11-06 Glaxo Group Ltd Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
KR20000067904A (ko) 1996-07-18 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 매트릭스 메탈로프로테아제의 포스피네이트계 억제제
WO1998007697A1 (en) 1996-08-23 1998-02-26 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
BR9713552A (pt) 1996-11-27 2000-01-25 Pfizer Derivados de pirimidina bicìclicos condensados
ATE272640T1 (de) 1997-01-06 2004-08-15 Pfizer Cyclische sulfonderivate
DK0977733T3 (da) 1997-02-03 2003-11-24 Pfizer Prod Inc Arylsulfonylaminohydroxamsyrederivater
AU5493598A (en) 1997-02-07 1998-08-26 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
YU37499A (sh) 1997-02-11 2002-09-19 Pfizer Inc. Derivati arilsulfonil hidroksamske kiseline
WO1998050356A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
EP0984692A4 (en) 1997-05-30 2001-02-21 Merck & Co Inc ANGIOGENESIS INHIBITORS
US5835420A (en) 1997-06-27 1998-11-10 Aplus Flash Technology, Inc. Node-precise voltage regulation for a MOS memory system
EP1005470B1 (en) 1997-08-22 2007-08-01 AstraZeneca AB Oxindolylquinazoline derivatives as angiogenesis inhibitors
WO1999016755A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
US6061742A (en) 1997-10-10 2000-05-09 Nortel Networks Corporation Computer network adaptor
KR20010082501A (ko) 1997-10-27 2001-08-30 개리 이. 프라이드만 4-아미노티아졸 유도체, 그 제조방법 및 싸이클린-의존성키나아제의 억제제로서의 이용방법
CN101328186A (zh) * 1997-11-11 2008-12-24 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
US6269027B1 (en) * 1998-04-14 2001-07-31 Honeywell, Inc. Non-volatile storage latch
BR9910792A (pt) 1998-05-29 2002-01-29 Sugen Inc Inibidores de quinase protéica 2-indolinona substituìda com pirrol
EP1140194A2 (en) 1998-12-23 2001-10-10 G.D. SEARLE & CO. Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia
DE10015193A1 (de) * 2000-03-27 2001-10-25 Infineon Technologies Ag Hochintegrierte System-on-Chip-Systeme mit nichtflüchtigen Speichereinheiten
ATE277933T1 (de) * 2000-06-06 2004-10-15 Pfizer Prod Inc Thiophenverbindungen zur verwendung als antikrebsmittel
US6995171B2 (en) * 2001-06-21 2006-02-07 Agouron Pharmaceuticals, Inc. Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
JP2005527511A (ja) 2002-03-01 2005-09-15 ファイザー インコーポレイテッド 抗血管形成剤として有用なチエノピリジンのインドリル−尿素誘導体およびその使用法

Also Published As

Publication number Publication date
US6869962B2 (en) 2005-03-22
IL165591A0 (en) 2006-01-15
HN2003000182A (es) 2004-07-27
EA200500018A1 (ru) 2005-06-30
DE60316440T2 (de) 2008-01-24
GEP20074033B (en) 2007-02-12
GT200300129A (es) 2004-03-17
ATE373665T1 (de) 2007-10-15
NO20045103L (no) 2005-02-17
CO5631447A2 (es) 2006-04-28
OA12865A (en) 2006-09-15
IS7552A (is) 2004-11-25
WO2003106462A1 (en) 2003-12-24
AU2003233134A1 (en) 2003-12-31
MXPA04011637A (es) 2005-03-07
US20040186126A1 (en) 2004-09-23
US20040009965A1 (en) 2004-01-15
MA27596A1 (fr) 2005-11-01
ECSP045483A (es) 2005-01-28
ZA200409862B (en) 2006-05-31
EA008255B1 (ru) 2007-04-27
PE20050123A1 (es) 2005-03-22
KR20060110011A (ko) 2006-10-23
EP1515975A1 (en) 2005-03-23
CA2489466A1 (en) 2003-12-24
BR0311806A (pt) 2005-03-29
DE60316440D1 (de) 2007-10-31
KR100714545B1 (ko) 2007-05-07
UA77303C2 (en) 2006-11-15
HRP20041173A2 (en) 2005-06-30
PL374542A1 (en) 2005-10-31
RS107504A (en) 2006-10-27
NZ537140A (en) 2006-10-27
KR20050008821A (ko) 2005-01-21
US7045528B2 (en) 2006-05-16
AP2004003184A0 (en) 2004-12-31
CN1671714A (zh) 2005-09-21
PA8575401A1 (es) 2004-05-07
US20060079548A1 (en) 2006-04-13
KR100671632B1 (ko) 2007-02-28
JP2005534669A (ja) 2005-11-17
TNSN04246A1 (fr) 2007-03-12
EP1515975B1 (en) 2007-09-19
TW200404070A (en) 2004-03-16
ES2290460T3 (es) 2008-02-16

Similar Documents

Publication Publication Date Title
AR039673A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metodos para su aplicacion
AR032621A1 (es) Compuestos derivados de tiofeno, metodo para su preparacion, composicion farmaceutica y uso en la fabricacion de medicamentos
AR038881A1 (es) Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos
AR036598A1 (es) Derivados de 4,5-dihidro-1h-pirazol que tienen potente actividad antagonista de cb1
ES2525763T3 (es) Derivados del ácido fenilalcanoico sustituido y sus usos para el tratamiento de enfermedades respiratorias
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
AR040031A1 (es) Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen
AR045738A1 (es) Derivados de bencimidazol n3 alquilados como inhibidores de mek
AR040398A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, composiciones farmaceuticas que los contienen y su uso para preparar un medicamento
AR038882A1 (es) Compuestos que modulan la actividad de ppar y composicion farmaceutica que los contiene
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
CY1105035T1 (el) Συγχωνευμενα με αρυλιο ή ετεροαρυλιο παραγωγα της ιμιδαζολης ως αντιφλεγμονωδεις και αναλγητικοι παραγοντες
AR038476A1 (es) Derivados de quinazolina
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
AR035479A1 (es) Derivados de eteres biarilicos y sus sales, composiciones farmaceuticas que los comprenden y procedimientos para el tratamiento de trastornos o afecciones
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
AR029150A1 (es) Un derivado de piperidina, su empleo, un procedimiento para prepararlo y una composicin farmaceutica que lo comprende.
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR004662A1 (es) Nuevos derivados de arilglicinamida, procedimiento para su preparacion, composiciones farmaceuticas que contienen estos compuestos y su utilizacionpara preparar medicamentos y combatir y prevenir enfermedades.
ES2178632T3 (es) Compuestos de benzoquinazolina farmaceuticamente activos.
PA8575001A1 (es) Fluorobenzamidas como inhibidores de maob
AR039651A1 (es) Derivados de isoquinolina
AR045793A1 (es) Compuestos derivados de 3-heterociclil-indol

Legal Events

Date Code Title Description
FA Abandonment or withdrawal